AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation

Chia-Wei Li1, Weiya Xia1, Seung-Oe Lim1, Jennifer L. Hsu1,2,3, Longfei Huo1, Yun Wu4, Long-Yuan Li1,2,3, Chien-Chen Lai1, Shih-Shin Chang1, Yi-Hsin Hsu1, Hui-Lung Sun1, Jongchan Kim1, Hirohito Yamaguchi1, Dung-Fang Lee1, Hongmei Wang1, Yan Wang1, Chao-Kai Chou1,2,3, Jung-Mao Hsu1, Yun-Ju Lai1, Adam M. LaBafi1,8, Qingqing Ding1, How-Wen Ko1,8, Fuu-Jen Tsai5, Chang-Hai Tsai1,2,5, Gabriel N. Hortobagyi9, and Mien-Chie Hung1,2,3,8

Abstract

Epithelial-to-mesenchymal transition (EMT) is an essential physiologic process that promotes cancer cell migration, invasion, and metastasis. Several lines of evidence from both cellular and genetic studies suggest that AKT1/PKBα, but not AKT2 or AKT3, serves as a negative regulator of EMT and breast cancer metastasis. However, the underlying mechanism by which AKT1 suppresses EMT remains poorly defined. Here, we demonstrate that phosphorylation of Twist1 by AKT1 is required for β-TrCP-mediated Twist1 ubiquitination and degradation. The clinically used AKT inhibitor MK-2206, which possesses higher specificity toward AKT1, stabilized Twist1 and enhanced EMT in breast cancer cells. However, we discovered that resveratrol, a naturally occurring compound, induced β-TrCP-mediated Twist1 degradation to attenuate MK-2206–induced EMT in breast cancer cells. Taken together, our findings demonstrate that resveratrol counteracts the unexpected metastatic potential induced by anti-AKT therapy and therefore suggest that the addition of resveratrol to an anti-AKT therapeutic regimen may provide extra support for limiting EMT.

Introduction

The highly conserved AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ of the AKT/PKB protein kinase family are known to promote tumor initiation and progression and are considered excellent targets for anticancer therapy (1–3). However, the oncogenic activities of the AKT isoforms are far more complex as exemplified by several lines of evidence demonstrating that AKT1 but not AKT2 or AKT3 serves as a negative regulator of epithelial-to-mesenchymal transition (EMT) and breast cancer metastasis. For instance, overexpression of AKT1 in breast cancer cells blocks cell motility and invasion (4, 5), whereas downregulation of AKT1 in MCF 10A cells decreases miR-200 abundance, thereby promoting TGFβ-induced EMT and stem cell–like phenotype (6). In AKT1−/− and ErbB2 transgenic mice, AKT1 activation accelerates mammary tumorigenesis but inhibits tumor invasion and metastasis (7). Moreover, Irie and colleagues demonstrated that knockdown of AKT1, but not AKT2, promotes insulin-like growth factor-1 (IGF1)-stimulated EMT and cell migration (4).

EMT is a complex reprogramming process of epithelial cells that plays an indispensable role in tumor invasion and metastasis, and characterized by well-defined features such as the loss of epithelial markers (E-cadherin and α- and γ-catenin), the gain of mesenchymal cell markers (fibronectin, vimentin, and N-cadherin), and the acquisition of migratory and invasive properties (8, 9). To date, several transcriptional repressors, for example, Zeb-1/2, Twist1, and Snail-1/2, have been reported to regulate EMT. Twist1, a highly conserved basic helix-loop-helix (bHLH) transcriptional repressor, induces EMT to promote breast tumor metastasis (10) and is transcriptionally regulated by EGFR/STAT3 (11, 12) and NFκB signaling (13). However, the regulatory mechanisms via posttranslational modification of Twist1 remain less understood.

To better understand AKT1-mediated EMT repression, we cross-analyzed gene expression profile of AKT isoforms using several public datasets. We found that low expression of AKT1 was highly associated with aggressive breast cancers and poor disease outcome. Moreover, our results indicated that AKT1 interacts with...
and phosphorylates Twist1 at S42, T121, and S123 to induce β-TrCP-mediated Twist1 degradation, leading to inhibition of EMT. Importantly, chronic exposure of breast cancer cells to AKT inhibitor, MK-2206, stabilizes Twist1 and induces EMT, whereas administration of a β-TrCP inhibitor, resveratrol, degrades Twist1 and attenuates their metastatic potential. Together, our findings offer new insights into the role of AKT1 in EMT inhibition and also identify a potential for adverse effect of inducing EMT when anti-AKT inhibitor is used in breast cancer treatment.

Materials and Methods
Western blotting and immunoprecipitation
Western blot analysis using total lysates or immunoprecipitates was performed as described previously (14) using the antibodies listed in Supplementary Table S2.

Gene expression analysis
The following databases were used to compare AKT isoform mRNA expression in breast cancer cells: Cancer Cell Line Encyclopedia (CCLE; ref. 15), Netherlands Cancer Institute (NKI) dataset (16), and the University of North Carolina (UNC) cohort (17, 18).

Cell lines and cell culture
All cell lines were obtained from the ATCC, independently validated by STR DNA fingerprinting at MD Anderson Cancer Center (Houston, TX), and maintained in DMEM/F-12 with 10% FBS. Stable cell lines were grown in the presence of an additional 500 mg/mL G418 (Invitrogen) or 1 μg/mL puromycin (Calbiochem).

In vitro kinase assay
Approximately 3 μg purified GST proteins were incubated with active AKT1 kinase (Upstate Biotechnology) and analyzed using SDS-PAGE and autoradiography.

Side population analysis
Side population analysis was performed as described previously (19). Briefly, cells were dissociated with Accutase, washed, and resuspended in ice-cold HBSS/5% FBS at a final concentration of 10^6 cells/100 μL. The CD44^+/CD24^- cell population was then determined by FACS.

Immunohistochemical staining
Immunohistochemical staining was performed as described previously (14). Human breast tumor tissue specimens were incubated with AKT1, β-TrCP, Twist1 or E-cadherin antibodies, and a bioin-conjugated secondary antibody and then incubated with an avidin–biotin–peroxidase complex. Visualization was performed using amino-ethylcarbazole chromogen. Fisher exact test and Spearman rank correlation coefficient were used for statistical analysis. A P value < 0.05 was considered statistically significant.

Mouse model of lung metastasis
Tumor metastasis assays were performed using an intravenous breast cancer mouse model as described previously (13). 4T1 cells (1 × 10^7) were injected into the lateral tail vein of Balb/c mice. Animals were weighed before each experimental end point, and lung nodules were stained with India ink, excised, and counted immediately. All animal procedures were conducted under the approval of the Institutional Animal Care and Use Committee at MD Anderson Cancer Center (Houston, TX; protocol number 10-14-07231). Detailed treatment protocol is described in the Supplementary Information.

Results
Pathologic expression of AKT isoforms in breast cancer cells
AKT activation is correlated with unfavorable clinical prognosis in many cancers including breast cancer. However, the roles of the AKT isoforms in breast cancer pathogenesis and their therapeutic potential have not been established. Thus, we examined the gene expression profile of the AKT isoforms by using a public dataset generated from 917 cancer cell lines (CCLE; ref. 15) and grouped them into epithelial and mesenchymal subtype based on the gene expression profile of CDH1, CDH2, vimentin, and fibronectin. In the mesenchymal subtype, AKT1 was significantly downregulated (Supplementary Fig. S1A), whereas AKT2 remains unchanged in breast and stomach cancer cells (data not shown). AKT3 was upregulated in the mesenchymal subtype in multiple cancers (Supplementary Fig. S1B). To further dissect the expression of AKT isoforms in breast cancer cell lines, unsupervised hierarchical clustering analysis was performed on the basis of the ESR2, ESR1, PGR, and EMT profiles. Strikingly, we were able to distinguish basal-like from luminal type breast cancer cells with high accuracy (90% properly segregated) from the gene list (Fig. 1A) based on their genetic characteristics. AKT1 was expressed at a lower level in either aggressive basal-like (vs. luminal) or mesenchymal-type breast cancer cells (vs. epithelial-type; Fig. 1B, middle and right), whereas AKT3 was significantly higher. Similarly, in another breast cancer dataset containing 54 cell lines (20), the basal-like and mesenchymal breast cancer subtypes were positively correlated with higher expression of AKT3 and inversely correlated with AKT1 (Supplementary Fig. S1C and S1D). Next, we asked whether a distinct group of clinical patient samples also share a differential expression pattern of AKT isoforms and found similar correlation using the NKI dataset (Fig. 1C; ref. 16) and the UNC cohort (Fig. 1D; refs. 17, 18). While coexpression of AKT1, AKT2, and AKT3 did not correlate with any specific breast cancer subtypes (Fig. 1C and D, left), a significant negative correlation was observed between AKT1 and aggressive phenotype (Fig. 1C and D, middle and right). To consolidate the differential regulation between the AKT isoforms, we first examined the phosphorylation status of GSK3β, which is a well-known substrate of AKT kinases (21), and found that phospho-GSK3β was similar in cells transiently expressing constitutively active form of AKT1 (myr-AKT1) or AKT2 (myr-AKT2; Supplementary Fig. S1E). Interestingly, only expression of myr-AKT1 activated the E-cadherin promoter in a dose-dependent manner (Fig. 1E), supporting the role of AKT1 in EMT inhibition. Consistently, overexpression myr-AKT1 but not myr-AKT2 or myr-AKT3 in MDA-MB-231 cells demonstrated an association with EMT regulation based on the expression of EMT markers (Fig. 1F). We further examined the protein expression of AKT isoforms in the metastatic breast cancer cohort by immunohistochemical staining. The recurrence-free survival of patients with higher expression of p-AKT S473, which represents the phosphorylation level of all three AKT1, 2, and 3 isoforms, was significantly worse than patients with lower p-AKT S473 expression (Fig. 1G). In contrast, total AKT1 expression was correlated with better patient survival (Fig. 1H). These results...
suggested that each of the three AKT isoforms have a distinct pathologic profile that is highly relevant to its functionality.

Twist1 physically associates with AKT1

Given the distinct regulatory nature of AKT isoform in breast cancer cells, we sought to distinguish their functionality by identifying their specific interacting partners. Immunoprecipitation of MDA-MB-231 cells stably expressing HA-myristoylated AKT1 and HA-myristoylated AKT2 indicated AKT1 but not AKT2 pulled down a significant amount of a 20-kDa protein (Supplementary Fig. S2A), which was identified by mass spectrometric analysis as Twist1 (with 72% sequence coverage). The complex formation between endogenous AKT1 and Twist1 was further validated by co-immunoprecipitation analysis (Supplementary Fig. S2B) and DuoLink labeling (Supplementary Fig. S2C).

In vitro GST pull-down assay indicated that Twist1 interacted directly with GST-AKT1 but not GST-AKT2 or GST alone (Supplementary Fig. S2D). As AKT1 inhibited EMT, we asked whether repression of EMT by AKT1 requires its interaction with EMT mediators, such as Twist1, FOXC2, E12, and Snail. AKT1 associated with Twist1 but not with the other EMT mediators (Supplementary Fig. S2E). A reverse immunoprecipitation also showed that AKT1 but not GSK3β, IKKα, or IKKβ interacted with Twist1 (Supplementary Fig. S3A). These results raise an interesting possibility that AKT1-mediated EMT repression maybe regulated through the physical and functional interaction with Twist1.

AKT1 phosphorylates Twist1 in vitro

Twist1 contains two AKT phosphorylation RxS/T motifs (22) at S42 and T121/S123, which are highly conserved across
species (Fig. 2A and Supplementary Fig. S3B). To determine which of these two motifs might be phosphorylated by AKT1, we expressed GST-Twist1 in two separate fragments: one containing amino acids 1–112 and the other 113–202 (Fig. 2B) and then subjected them to an in vitro kinase assay with AKT1. AKT1 strongly phosphorylated both GST-Twist1 fragments (Fig. 2C) but phosphorylation was abolished when we mutated the consensus motif on Twist1. To pinpoint the phosphorylation potential in context of full-length Twist1, GST-Twist1 S42A (S42A), VA (T121V/S123A), and AVA (S42A/T121V/S123A) mutants were subjected to an in vitro kinase assay. Substitutions in both AKT phosphorylation motifs (Twist1 VA) abolished AKT1-mediated phosphorylation (Fig. 2D), whereas substitutions in one or the other motif (S42A or T121V/S123A) had little or no effect on Twist1 phosphorylation (Fig. 2D). These results suggested that complete phosphorylation of Twist by AKT1 in vivo requires phosphorylation at S42, T121, and S123.

**AKT1 phosphorylates Twist1 in vivo**

To recapitulate AKT1-mediated Twist1 phosphorylation in vivo, we coexpressed Flag-Twist1 and HA-tagged wild-type AKT1 (WT), dominant negative AKT1 (DN), or myr-AKT1 followed by immunoprecipitation with anti-Flag antibody and immunoblotting with phospho-AKT substrate antibody and phospho-RxRxxS/T antibody (Supplementary Fig. S3C). Twist1, but not other EMT regulators, was phosphorylated in the presence of myr-AKT1 (Supplementary Fig. S3D). Similar to the observations in vitro (Fig. 2D), mutation of either S42 alone or both T121/S123 in Twist1 did not affect its overall level of phosphorylation by AKT1, whereas mutation of all three sites completely abrogated its phosphorylation (Fig. 2E). Myr-AKT1 induced a noticeable mobility shift of wild-type and S42A mutant Twist1 but not Twist1-AVA or Snail (Supplementary Fig. S3E). In addition, AKT1 and AKT2 governed Twist1 functionality through differential phosphorylation, in which AKT2 primarily phosphorylated Twist1 at S42 (Supplementary Fig. S3F), whereas AKT1 phosphorylated...
Twist1 at all three sites both in vitro and in vivo (Fig. 2D and E). The observed Twist1 S42 by AKT2 is in agreement with previously reported Twist1 S42 phosphorylation by AKT (23).

To further differentiate AKT1- from AKT2-mediated Twist1 phosphorylation, we reexpressed AKT1 or AKT2 in the AKT1/2/3 knockdown cells. AKT1, AKT2, and AKT3 were specifically knocked down in MDA-MB-231 cells using pGZIP vector (Supplementary Fig. S3G). AKT1 WT, AKT1 KD, AKT2 WT, and AKT2 KD were then reexpressed (Supplementary Fig. S3H). Cells reexpressing AKT1 had Twist1 S42, T121 and S123 phosphorylation, whereas those reexpressing AKT2 only had Twist1 phosphorylation at S42 (Fig. 2F). IGF1-induced phosphorylation of Twist1 was inhibited in those treated with MK-2206, suggesting that Twist1 phosphorylation is regulated by PI3K signaling cascade (Fig. 2G).

The expression of Twist1 in tumor cells is regulated by PI3K signaling cascade (Fig. 2G).

Phosphorylation by AKT1 is required for Twist1 degradation

First, we asked whether AKT1-mediated phosphorylation of Twist1 affects its expression levels. In AKT1-deficient mouse embryonic fibroblasts (MEF), Twist1 expression was higher compared with that in WT MEFs (Fig. 3A). In contrast, Twist1 expression was downregulated in the HeLa cells stably expressing myr-AKT1 but not myr-AKT2, even though GSK3β was appropriately phosphorylated by both AKT1 and AKT2 (Fig. 3B). Downregulation of AKT1 but not AKT2 by shRNA upregulated Twist1 expression (Fig. 3C, right). Consistent with an earlier study (6), silencing AKT1 but not AKT2 expression induced EMF mutant phenotype in MCF 10A cells (Fig. 3C, left).

Next, we measured the protein turnover rate in the presence of cycloheximide to determine the effect of AKT1-mediated phosphorylation on Twist1 protein stability. The turnover rate of Twist1 in myr-AKT1-expressing cells was much faster compared with those in myr-AKT2-expressing or empty vector control cells (Fig. 3D). We further examined the protein half-life of Twist1 and its three phospho-deficient variants (S42A, VA, and AVA) and found that the half-life of Twist1 AVA was significantly longer compared with that of Twist1 WT and Twist1 DDDD phosphorylation-mimic mutant in the presence of myr-AKT1 (Fig. 3E).

AKT1 modulates β-TrCP-mediated Twist1 degradation

We noted that Twist1 contains one β-TrCP destruction box, DψψXXX, which is also present in β-catenin, IκB, and Snail (Fig. 4A) (24, 25). Overexpression of β-TrCP in HEK293 cells led to a rapid degradation of Twist1 (Supplementary Fig. S4A). Mutation of this motif (DLSLSN to DALSNA: Fig. 4B) or knockdown of β-TrCP (Supplementary Fig. S4B) stabilized Twist1 expression. Similar to many β-TrCP substrates, induction of β-TrCP expression in MDA-MB-468 (Fig. 4C) and HeLa cells (Supplementary Fig. S4C) by ciglitazone (CZ), troglitazone (TG), or resveratrol (26, 27) reduced Twist1 expression, supporting that β-TrCP upregulation mediates Twist1 degradation. A double thymidine (Fig. 4D, quantitation of Supplementary Fig. S4D) and thymidine/nocodazole assay (Supplementary Fig. S4E) indicated that Twist1 protein but not mRNA was degraded during S to G2–M phase. Moreover, downregulation of β-TrCP expression stabilized Twist1, suggesting that β-TrCP is an authentic E3 ligase that regulates Twist1 degradation at S-phase.

To further validate how AKT1 is involved in β-TrCP-mediated Twist1 destabilization, we ectopically expressed β-TrCP WT and β-TrCP AF (a β-TrCP variant that lacks the F-box domain) and examined their effect on Twist1 ubiquitination. Expression of β-TrCP WT but not β-TrCP AF induced specific ubiquitination of Twist1 WT. Twist1 AVA was not ubiquitinated (Fig. 4E) in either β-TrCP WT or β-TrCP ΔF-expressing cells. In addition, coexpression of β-TrCP facilitated AKT1-mediated Twist1 degradation (Fig. 4F). Because the degradation machinery is enriched in the cytoplasm, we next asked whether AKT1-mediated Twist1 phosphorylation regulated by subcellular localization. Nonphosphorylation-mimic Twist1 AVA, which is resistant to 26S proteasome-mediated degradation, primarily localized to the nucleus (Fig. 4G). Likewise, expression of myr-AKT1 DN (dominant negative), which blocks endogenous AKT1 activity, led to an accumulation of nonphosphorylated Twist1 WT in the nucleus (Fig. 4G and Supplementary Fig. S5A).

Cellular fractionation assay also demonstrated the nuclear translocation of nonphosphorylated Twist1 AVA variant (Fig. 4H). Our findings suggest that AKT1-mediated phosphorylation of Twist1 is required for its translocation from the nucleus to the cytoplasm where degradation occurs.

Twist1 AVA is a potent inducer of EMT

Because Twist1 is a key mediator during EMT progression, we also investigated the effect of AKT1-mediated Twist1 phosphorylation in EMT using Twist1 phosphorylation-deficient (Twist1 AVA) and phosphorylation-mimic (Twist1 DDDD) mutants. To this end, we established stable transfectants with empty vector (EV), Twist1 WT, and AVA and DDD Twist1 mutants in MCF7 breast cancer cells, in which the basal level of endogenous Twist1 WT is low. Of the 35 clones screened, more than 15 clones expressed Twist1 WT with little or no effect on E-cadherin expression and no apparent morphologic changes that resemble EMT. Likewise, the Twist1 DDDD stable transfectants did not induce any E-cadherin loss or EMT phenotype. Interestingly, half of the 20 neomycin-resistant clones of Twist1 AVA transfectants underwent morphologic changes that resembled EMT. Stable transfectants with similar Twist1 expression levels were used for comparison (Fig. 5A and B and Supplementary Fig. S5B and S5C). To exclude the random effect from stable transfectant selection, we infected MDCK cells with replication-incompetent retroviruses expressing Flag-Twist1 WT, AVA, and DDD. In both MCF7 and MDCK cells, Twist1 AVA induced significantly downregulated E-cadherin and upregulated N-cadherin expression (Fig. 5A and B and Supplementary Fig. S5D). Vimentin was also selectively expressed in Twist1 AVA-expressing cells (Fig. 5B, and Supplementary Fig. S5C). RT-PCR analysis indicated that E-cadherin mRNA level was partially reduced in MCF7-Twist1 WT cells but completely abrogated in MCF7-Twist1 AVA cells (Fig. 5C). These results suggest that AKT1-mediated phosphorylation of Twist1 suppresses expression of several EMT markers such as N-cadherin and vimentin and derepresses Twist1-repressed E-cadherin. Blocking Twist1 phosphorylation as exemplified by the Twist1 AVA-mutant-induced expression of EMT markers.

To further validate the association between Twist1 AVA mutant and EMT phenotype, we performed several EMT-related functional assays using MCF7 stable transfectants. Although cell proliferation rate of Twist1 variants remained similar (Supplementary Fig. S5E and S5F), cell invasion ability by a Transwell assay was significantly enhanced in MCF7-Twist1 AVA transfectants. MCF7-Twist1 AVA cells also displayed accelerated migration by wound healing assay compared with the WT and DDD mutant under time-lapse microscopy (Supplementary Fig. S6A). Twist1 AVA demonstrated aggressive phenotype as indicated by the high percentage of migrating cells (Supplementary Fig. S6B). To further
validate the migration ability was due to the loss of E-cadherin, we restored E-cadherin into two independent Twist1 AVA clones to revert Twist1 AVA-induced EMT (Supplementary Fig. S6C). Because EMT is usually accompanied by an increase in cancer stem cell properties, we also conducted stem cell analysis and found that CD24+/CD44+ population (Fig. 5D) and mammosphere formation (Fig. 5D, inset) was higher in cells expressing Twist1 AVA than in those expressing WT or DDD-mutant Twist. Moreover, the percentage of Twist1 AVA-expressing cells that underwent adriamycin-induced apoptosis was significantly less compared with that of Twist1 S42A and VA (Supplementary Fig. S6D). Taken together, blocking AKT1-mediated Twist1 phosphorylation enhances EMT phenotypic changes that resemble AKT1-induced EMT repression.

Figure 3.
AKT1 enhances Twist1 ubiquitination and degradation. A, protein expression of Twist1 in wild-type and AKT1-deficient MEFs. B, overexpression of myr-AKT1 and myr-AKT2 in HeLa cells by retrovirus infection. Cell lysates from these stable clones were subjected to Western blotting with the indicated antibodies. C, phase contrast imaging of EMT morphotypic changes in MCF 10A shCTRL, shAKT1, and shAKT2 stable cells treated with 100 nmol/L TGF-β for 6 hours. Protein expression was analyzed by Western blot analysis (right). D, Western blot analysis of Twist1 protein stability with indicated transient transfection. Cells were then treated with 20 μmol/L cycloheximide (CHX) at the indicated intervals. E, protein half-life of Twist1 WT, AVA, and DDD was determined as described in Fig. 3D.
Figure 4. AKT1 induces β-TrCP-mediated Twist1 degradation. A, sequence alignment of β-TrCP destruction motif. Twist1 contains one putative β-TrCP recognition motif (DSyXXS). D, aspartic acid; S, serine; y, hydrophobic; X, any amino acid. B, pulse-chase experiment of Twist1 WT and 2SA protein stability using cycloheximide (CHX). C, MDA-MB-468 cells were treated with CG, TG, and resveratrol at the indicated concentration for 48 hours and subjected to Western blotting with the indicated antibodies. D, quantification of Twist1 expression during cell-cycle progression. HeLa cells carrying siCTRL or siβ-TrCP were synchronized using double thymidine block. Protein expression was measured by Western blot analysis and quantified by densitometer. The full figure is presented in Supplementary Fig. S4D. E, covalently conjugated His-ubiquitin of Twist1 was pulled down by Ni2+-agarose beads under denaturing condition and analyzed by Western blot analysis with indicated antibodies. F, Western blot analysis of Twist1 degradation in HEK-293T cells. G, subcellular localization of Twist1 WT, Twist1 AVA, and Twist1 DDD. HA-Twist1 WT, AVA, and DDD were transiently expressed in HeLa cells. The localization of Twist1 variants was imaged under a fluorescent microscope. H, cell fractionation analysis of Twist1 variants.
To consolidate the role of Twist1 in AKT1-mediated EMT repression, we knocked down Snail and Twist1 in shAKT1 clone and found that downregulation of Twist1 but not Snail abolished shAKT1-induced EMT (Supplementary Fig. S6E). We also stably expressed myr-AKT1 DN in MCF 10A (shCTRL) and two Twist1 knockdown stable clones (shTW-1 and shTW-2) (13). Myr-AKT1 DN increased Twist1 expression and enhanced TGFβ-induced EMT in MCF 10A cells as measured by downregulation of E-cadherin and upregulation of vimentin and N-cadherin expression. However, knocking down Twist1 in MCF 10A cells as measured by downregulation of E-cadherin and upregulation of vimentin and N-cadherin expression. However, knocking down Twist1 in Twist1-expressing cells, whereas cells that received shControl (shC) showed no effect (Fig. 5E). Thus, expression of Twist1 in MCF 10A cells is required for TGFβ/myr-AKT1 DN-induced EMT, establishing a role of Twist1 in the AKT1-mediated EMT repression.

Next, we asked whether AKT1 DN increases the metastatic potential of breast cancer in vivo, and if so, whether the AKT1 DN-induced Twist1 expression plays a role in this process. Results from an in vivo experimental metastasis assay by a lung colonization xenograft model showed that myr-AKT1 DN overexpression clones in MCF10A cells. F, 4T1-Luc cells with myr-AKT1 DN and two shTwist1-stable clones were injected into female nude mice via the tail vein. Error bars, the mean ± SD of five mice.

AKT1 controls the molecular switch of Twist1 by T121 and S123 phosphorylation

To differentiate AKT2-induced EMT via Twist1 S42 phosphorylation, a series of functional analyses was performed to distinguish the isoform-specific regulation in the context of Twist1. Twist1 S42A exhibited similar protein stability (Supplementary EV A).
Fig. S7A) and ubiquitination (Supplementary Fig. S7B) compared with the wild-type Twist1. Interestingly, mutation of the second motif on Twist1 S42A (Twist1 AVA) robustly stabilized Twist1 by blocking ubiquitination. These results suggest that T121 and S123 phosphorylation by AKT1 favors β-TrCP recognition for protein degradation. We performed qChIP (Supplementary Fig. S7C) and luciferase assay (Supplementary Fig. S7D) to evaluate the transcriptional activities of the Twist1 variants on the E-cadherin promoter. We showed that Twist1 S42A by transient transfection reduced its DNA binding ability and derepressed the transcriptional activity of the E-Cadherin promoter, which is in line with prior studies showing AKT2 phosphorylates Twist1 at S42 to induce EMT (28). Neither DNA binding nor transcriptional repression of the E-cadherin promoter was affected by the Twist1 VA (T121V/S123A) mutant, which suggests that T121/S123 phosphorylation per se does not affect Twist1 binding affinity. Results from functional assays using Twist MCF7 stable transfectants by retrovirus, however, indicated that Twist1 S42A lost its EMT potential, whereas Twist1 AVA induced EMT phenotypic change (Supplementary Fig. S7E) as well as cell invasion (Supplementary Fig. S7F). The half-life of Twist1 S42A mutant was much shorter than that of the AVA mutant (Supplementary Fig. S7A). The additional phosphorylation at T121/S123 in Twist1 S42A likely enhances its degradation by β-TrCP in the stable transfectants, reducing its ability to induce EMT. Altogether, we propose a model (Supplementary Fig. S7G) as follows: AKT2 phosphorylates Twist1 at S42, which reduces E-Cadherin expression to induce EMT, whereas AKT1 catalyzes two additional phosphorylation at T121 and S123, allowing β-TrCP to degrade Twist1, which leads to inhibition of EMT.

Correlation of AKT1, β-TrCP, Twist1, and E-cadherin in human tumor tissues

To validate the pathologic relevance of the identified mechanism, we studied the expression of AKT1, β-TrCP, Twist1, and E-cadherin in 104 human metastatic breast tumor specimens by IHC staining. Twist1 was detected in 13 of 39 specimens with high AKT1 expression but in 39 of the 45 specimens with low AKT1 expression, indicating that there is an inverse correction between AKT1 and Twist1 expression. Consistent with this finding, we found that AKT1 expression correlated with β-TrCP and E-cadherin expression (Supplementary Fig. S8 and Table S1).

Inhibition of AKT1 induces Twist1 upregulation and metastatic potential

Multiple AKT inhibitors have been tested in clinical trials as anticancer agents (29). The model shown in Supplementary Fig. S7G raised the concern that the use of AKT inhibitors as anticancer agents could potentially enhance EMT/metastasis while suppressing tumor growth. To this end, we tested this potential adverse effect of a clinically used AKT inhibitor, MK-2206, which possesses differential inhibition toward specific AKT isoform (selective inhibitor of AKT1, AKT2 and AKT3 with IC50 of 5, 12, and 65 nmol/L, respectively; 30). As breast cancer cells with lower ratios of AKT1/AKT2 are less sensitive to MK-2206 (31), we sought to determine whether AKT1 inhibition by MK-2206 has potential to induce EMT via Twist1 upregulation in breast cancer cells. MCF10A cells were treated with 0.2 μmol/L MK-2206, which enhanced TGFβ-induced EMT (Fig. 6A, lane 4, 8, and 12 and Supplementary Fig. S9A). MK-2206 alone also induced EMT in MCF10A cells but required a longer stimulation than TGFβ treatment (Fig. 6A, lane 3, 7 and 11). Continuous treatment with MK-2206 alone to passage 3 (3 days/passage) led to late EMT morphologic changes similar to those by TGFβ. In fact, MK-2206 mediated EMT primarily through inhibition of AKT1 as knockdown of AKT2 and AKT3 had no effect on the expression of EMT markers (Supplementary Fig. S9B). Consistent with our results from AKT1 knockdown cells (Fig. 3C), inhibition of AKT1 by MK-2206 increases Twist1 stability by blocking Twist1 degradation (Fig. 6A). To determine whether stabilization of Twist1 is required for MK-2206-mediated EMT, MCF 10A cells carrying shCTRL or shTwist1 (shTW) were treated with MK-2206 for 10 days. Downregulation of Twist1 inhibited MK2206-mediated cell migration, invasion, and acquisition of EMT phenotype (Fig. 6B), suggesting an indispensable role of Twist1 in MK-2206-mediated phenotypic changes associated with EMT.

As the protein stability of Twist1 is tightly regulated by β-TrCP (Fig. 4C and Supplementary Fig. S4C), we asked whether destabilization of Twist1 by β-TrCP inhibitor, resveratrol, would reduce MK-2206–mediated EMT. We first treated MCF10A cells with MK-2206 to induce EMT followed by resveratrol (10 μmol/L) for 2 days. Resveratrol downregulated Twist1 and reverted MK-2206–mediated phenotypic changes associated with EMT (Fig. 6C). At a concentration of 10 μmol/L, resveratrol inhibited MK-2206–mediated cell invasion (Fig. 6D) and migration ability (Fig. 6E). Similar results were observed in 4T1 cells (Supplementary Fig. S9C). The possibility that resveratrol decreases the MK-2206–mediated aggressiveness was further explored by investigating the effects of resveratrol on tumor metastasis in an animal model. We inoculated 4T1 cells in Balb/c mice by tail vein injection (13). Tumor-bearing mice were then treated with or without MK-2206 and/or resveratrol. The metastatic nodules in the lungs were resected from each mouse and quantified by a dissecting microscope (Fig. 6F). The number of lung metastasis was significantly reduced in mice cotreated with both MK-2206 and resveratrol but not in mice that received each agent alone (Fig. 6G). In addition, the combined therapy of MK-2206 and resveratrol also prolonged mice survival by 20% (Fig. 6H). These observations suggest that Twist1 is a key factor in MK-2206–induced EMT, cell migration/invasion, and lung colonization in breast cancer and that destabilization of Twist1 by inducing β-TrCP through resveratrol enhances the therapeutic efficacy of MK-2206 for breast cancer treatment (Fig. 6I).

Discussion

Some discrepancies observed in AKT1’s role in breast cancer metastasis have been reported. For instance, overexpression of AKT1 suppresses tumor invasion but accelerates ErbB2-mediated mammary tumorigenesis (7). In other studies, AKT1 knockout impaired lung metastasis in MMTV-ErbB2/Neu and MMTV-PyMT transgenic mice (32, 33). While this may be attributed to the differences between the transgenic models tested, one possibility could be that knockout of AKT1 already compromised the ErbB2- and PyMT-induced primary tumor formation, which may in turn impair AKT1-mediated EMT and metastasis inhibition.

Consistent with the literature (4–6, 34, 35), our study provides a comprehensive pathologic and mechanistic understanding of the complexity of AKT isoform regulation in breast cancer EMT. Multiple dataset analysis identified the inhibitory nature of AKT1 in EMT, which was further validated by patient sample analysis in which a correlation between AKT1 expression and improved...
patient survival in invasive breast cancer cohorts was observed. In vitro and in vivo studies using the Twist1 AVA mutant demonstrated that AKT1 mediates EMT inhibition in breast cancer cells, further supporting an inverse relationship between AKT1 expression and EMT from gene expression analysis. It is worthwhile to mention that stable clones of Twist1 variant were selected with equal expression level; however, Twist1 AVA still exhibited obvious EMT, suggesting other function of Twist1 AVA may exist to stimulate EMT in addition to its ability to increase Twist1 protein stability. Although AKT1 inhibits EMT in breast cancer, AKT1 was shown to induce EMT in squamous cancer and sarcoma (36–38). Thus, it is of importance to understand how cell-type–specific AKT isoform expression, localization, and activities elicit diverse functions in cancer cells.

AKT2 phosphorylates Twist1 at S42 to enhance Twist1-mediated E-cadherin suppression (23). As AKT1 also phosphorylates Twist1 at S42, AKT1 may exert dual and contradictory influences on Twist1. According to our data, the complexity may be minimal as Twist1 protein expression is downregulated as long as AKT1 is expressed in breast cancer. These results are also in agreement with many published research showing that AKT1 inhibits EMT in breast cancer (4–6, 34, 35). Hence, we believe that Twist1 S42-mediated EMT induction by AKT1 may exist but is outpaced by AKT1-mediated negative regulation through T121 and S123 phosphorylation in breast cancer.

In summary, we have identified a novel AKT1/β-TrCP/Twist1/E-cadherin signaling axis in breast cancer cells (Supplementary Table S1). The AKT1- and AKT2-specific EMT regulation of Twist1 phosphorylation appear to have differential effects depending on the cellular context. Dissecting the effect of each AKT isoform, in this case, AKT1, enabled us to further understand how breast cancer cells undergo EMT and reach metastatic potential. Moreover, resveratrol may provide therapeutic benefits by limiting the metastatic potential when administering MK-2206.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figure 6.

Twist1 is required for AKT1-mediated EMT repression. A, MCF 10A cells were continuously treated with or without TGFβ or MK-2206. Phenotypic changes were examined by Western blot analysis with the indicated antibodies. B, MCF10A cells harboring shCTRL and shTwist1 were treated with 0.2 μmol/L or 0.5 μmol/L MK-2206 for 10 days and subjected to Western blotting with the indicated antibodies. C, resveratrol reduces MK-2206-induced EMT. MCF 10A cells were continuously treated with or without MK-2206 or resveratrol and subjected to Western blotting with the indicated antibodies. D and E, the number of migrating cells and their distance of migration (arbitrary unit) calculated from three independent views. F, representative photograph of metastatic lung nodules. 4T1 cells (1 × 10^5 cells/0.1 mL) were injected into the lateral tail vein of Balb/c female mice. MK-2206 and resveratrol were then administered orally at a dosage of 200 mg/kg (n = 6/group) per day for 21 days. Mice were sacrificed, and the lungs were stained with India ink and resected for imaging. G, quantification of the lung nodules. Error bars, ± SD for n = 6. H, the survival time of mice in F. Survival curve was plotted by Kaplan–Meier analysis. I, schematic diagram showing the combinatorial strategy of utilizing resveratrol to overcome MK-2206-induced metastatic potential.
Authors' Contributions
Development of methodology: C.-W. Li, L. Huo, L.-Y. Li, Y.-H. Hsu, A.M. Lalla
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.-W. Li, W. Xia, S.-O. Lim, Y. Wu, C.-C. Lai, S.-S. Chang, C.-K. Chou, Y.-J. Lai, Q. Ding, H.-W. Ko
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.-W. Li, W. Xia, S.-O. Lim, L.-Y. Li, Y.-H. Hsu, A.M. Lalla, Q. Ding, G.N. Hortobagyi, M.-C. Hung
Writing, review, and/or revision of the manuscript: C.-W. Li, J.L. Hsu, H. Wang, A.M. Lalla, G.N. Hortobagyi, M.-C. Hung
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-Y. Li, J.-M. Hsu, Y.-J. Lai, F.-J. Tsai, C.-H. Tsai, G.N. Hortobagyi
Study supervision: G.N. Hortobagyi, M.-C. Hung

Performing (an experiment to contribute data): J. Kim

References
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation

Chia-Wei Li, Weiya Xia, Seung-Oe Lim, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-15-1941

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2016/01/12/0008-5472.CAN-15-1941.DC1

Cited articles
This article cites 38 articles, 18 of which you can access for free at: http://cancerres.aacrjournals.org/content/76/6/1451.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.